Format

Send to

Choose Destination
AJR Am J Roentgenol. 2012 Apr;198(4):737-45. doi: 10.2214/AJR.11.7483.

Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST.

Author information

1
Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Mizuki_Nishino@dfci.harvard.edu

Abstract

OBJECTIVE:

The purpose of this article is to review cancer- and therapy-specific tumor response assessment criteria used in clinical trials and in practice, with illustrative case examples, and to discuss future directions toward "personalized" tumor response assessment.

CONCLUSION:

Although Response Evaluation Criteria in Solid Tumors will remain as the primary generalized criteria for response assessment, newer cancer- and therapy-specific criteria will play an important role in providing state-of-the-art response assessment of tumor following molecular targeted therapy and will contribute to personalized cancer care in the era of molecular medicine.

PMID:
22451534
PMCID:
PMC3369700
DOI:
10.2214/AJR.11.7483
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center